Elevated expression of cancer/testis antigen FSIP1 in ER-positive Breast Tumors

Chapman, KB; Mj, Prendes; Jl, Kidd; Sternberg, Hal; West, Michael; Wagner, Joseph

doi:10.2217/bmm.13.58

Cited by 16 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RARA, Retinoic Acid Receptor Alpha, is a protein-coding gene that has been implicated in the development of hematological and solid tumor malignancies, including lung cancer [20]. Fibrous Sheath Interacting Protein 1 (FSIP1) is also a protein coding gene, and increased mRNA expression of this gene has been associated with breast tumors [21]. FSIP1 has also been associated with poorer prognosis in lung cancers [22].…”

Section: Discussionmentioning

confidence: 99%

Novel DNA methylation sites associated with cigarette smoking among African Americans

et al. 2019

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Novel DNA methylation sites associated with cigarette smoking among African Americans

et al. 2019

View full text Add to dashboard Cite

“…Fibrous sheath interacting protein 1 (FSIP1) is a cancer/testis antigen (16) expressed in the majority of breast cancers, bladder cancers, and nonsmall cell lung cancer (17)(18)(19). Our previous findings and those of others show that high FSIP1 expression is associated with increased invasiveness and poor prognosis in breast cancer (19,20). We found that FSIP1 interacts with HER2, and that FSIP1 silencing inhibits the proliferation and invasiveness of ER + or HER2 + breast cancer cells (21).…”

mentioning

confidence: 70%

“…FSIP1 is a cancer/testis antigen and its expression is associated with poor prognosis in breast cancer (19,20). We have previously shown that FSIP1 promoted proliferation and invasion of ER + and HER2 + breast cancer cells (19).…”

Section: Discussionmentioning

confidence: 99%

FSIP1 regulates autophagy in breast cancer

Liu

Sun

Yang

et al. 2018

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Fibrous sheath interacting protein 1 (FSIP1) is a cancer antigen expressed in the majority of breast cancer tissues and is associated with poor prognosis. However, the role of FSIP1 in the progression and drug sensitivity of triple-negative breast cancer (TNBC) has not been explored. Here, we show that FSIP1 deficiency by shRNA-mediated knockdown or CRISPR-Cas9–mediated knockout significantly inhibits the proliferation and invasion of TNBC cells and impairs chemotherapy-induced growth inhibition in vivo. Computational modeling predicted that FSIP1 binds to ULK1, and this was established by coimmunoprecipitation. FSIP1 deficiency promoted autophagy, enhanced AMP-activated protein kinase (AMPK) signaling, and decreased mechanistic target of rapamycin (mTOR) and Wnt/β-catenin activity. In contrast, knockdown of AMPK or inhibition of autophagy restored the sensitivity to chemotherapy drugs in TNBC cells. Our findings uncover a role of FSIP1 as well as mechanisms underlying FSIP1 action in drug sensitivity and may, therefore, aid in design of TNBC therapies.

show abstract

“…It is a definite protein-coding gene. 13 FSIP1 has been reported to anomalously engage in the tumor cell mitotic network. 21 Moreover, there is evidence to support FSIP1 as a potential target for steroid receptor coactivator-3, a gene responsible for cancer progression and poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Fibrous sheath interacting protein 1 overexpression is associated with unfavorable prognosis in bladder cancer: a potential therapeutic target

Sun¹,

Zhao²,

Zeng³

et al. 2017

OTT

View full text Add to dashboard Cite

The study aimed to investigate the clinical significance of fibrous sheath interacting protein 1 (FSIP1) in bladder cancer, and its potential relevance to the survival of patients with bladder cancer. A total of 225 surgical excised-bladder cancer tissues were collected from the patients with the follow-up data >5 years. The FSIP1 expressions were assayed using immunohistochemistry. The messenger RNA (mRNA) and/or protein levels of FSIP1 in fresh bladder tumor tissues as well as bladder cancer cell lines were measured by quantitative real-time polymerase chain reaction (PCR) and Western blotting analysis. The correlation of FSIP1 expression with clinicopathological parameters was also evaluated. Western blotting analysis revealed that FSIP1 protein was detected in 94.1% (16/17) of bladder tumor specimens and in all three bladder cancer cell lines (5637, BIU-87, and T24 in particular), with significantly higher expression than those of their controls. Quantitative real-time PCR demonstrated an increased FSIP1 mRNA expression level in bladder cancer tissues than in normal adjacent tissues (P=0.012). FSIP1 overexpression showed good correlation with tumor stage and lymph node metastasis (P=0.027 and 0.000, respectively). Positive FSIP1 expression was independently associated with an unfavorable overall and disease-free survival by multivariate Cox regression (P=0.037 and 0.019, respectively). FSIP1 overexpression is associated with unfavorable prognosis in patients with bladder cancer. Thus, FSIP1 represents a potential therapeutic or predictive target for bladder cancer.

show abstract

Elevated expression of cancer/testis antigen FSIP1 in ER-positive Breast Tumors

Abstract: The prevalence and uniformity of FSIP1 expression in breast tumors, taken together with the highly restricted expression in normal tissues, suggests that FSIP1 may be an attractive target for breast cancer immunotherapy.

Cited by 16 publications

References 37 publications

Novel DNA methylation sites associated with cigarette smoking among African Americans

Novel DNA methylation sites associated with cigarette smoking among African Americans

FSIP1 regulates autophagy in breast cancer

Fibrous sheath interacting protein 1 overexpression is associated with unfavorable prognosis in bladder cancer: a potential therapeutic target

Contact Info

Product

Resources

About